{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:38:12Z","timestamp":1777934292703,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,9,26]],"date-time":"2017-09-26T00:00:00Z","timestamp":1506384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>5-fluorouracil and capecitabine are chemotherapeutic agents commonly used to treat solid malignancies. Increased susceptibility to 5-fluorouracil or capecitabine, caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, or other genetic mutations in the enzymes that metabolize 5-fluorouracil can lead to severe life-threatening toxicities and are typically manifested by an early onset of symptoms. We report and discuss the management and outcome of capecitabine toxicity with the recently FDA approved antidote, uridine triacetate (Vistogard), in a 57-year-old female breast cancer patient with homozygous dihydropyrimidine dehydrogenase deficiency who received treatment beyond the recommended 96\u2009h window from the last dose of capecitabine.<\/jats:p>","DOI":"10.1177\/1078155217732141","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T02:27:59Z","timestamp":1506479279000},"page":"234-238","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Successful use of uridine triacetate (Vistogard) three weeks after capecitabine in a patient with homozygous dihydropyrimidine dehydrogenase mutation: A case report and review of the literature"],"prefix":"10.1177","volume":"25","author":[{"given":"Mira","family":"Zurayk","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huntington Memorial Hospital, Pasadena, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8209-3914","authenticated-orcid":false,"given":"Yi-Kong","family":"Keung","sequence":"additional","affiliation":[{"name":"UCLA Hematology-Oncology Clinic, Alhambra, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huntington Memorial Hospital, Pasadena, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eddie HL","family":"Hu","sequence":"additional","affiliation":[{"name":"UCLA Hematology-Oncology Clinic, Alhambra, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,9,26]]},"reference":[{"key":"bibr1-1078155217732141","doi-asserted-by":"crossref","unstructured":"Ma W, Saif W, El-Rayes B, et al. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.\n                      Cancer\n                      2017; 123: 345\u2013356.","DOI":"10.1002\/cncr.30321"},{"key":"bibr2-1078155217732141","first-page":"43","volume":"5","author":"Andreica I","year":"2015","journal-title":"J Hematol Oncol Pharm"},{"key":"bibr3-1078155217732141","doi-asserted-by":"crossref","unstructured":"Santos C, Morgan BW and Geller RJ. The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV\/AIDS with uridine triacetate.\n                      Am J Emerg Med\n                      2017; 35: 802\u2013803.","DOI":"10.1016\/j.ajem.2016.11.038"},{"key":"bibr4-1078155217732141","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100434"},{"key":"bibr5-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3063-1"},{"key":"bibr6-1078155217732141","doi-asserted-by":"crossref","unstructured":"Vaudo CE, Gil B, Galuski K, et al. Early-onset 5-fluorouracil toxicity in a patient negative for dihydropyrimidine dehydrogenase mutations: the clinical course of reversal with uridine triacetate.\n                      Pharmacotherapy\n                      2016; 36: 178\u2013182.","DOI":"10.1002\/phar.1841"},{"key":"bibr7-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118830"},{"key":"bibr8-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1007\/BF01799841"},{"key":"bibr9-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10599"},{"key":"bibr10-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)00261-X"},{"key":"bibr11-1078155217732141","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.03.02"},{"key":"bibr12-1078155217732141","first-page":"1531","volume":"34","author":"Papanastasopoulos P","year":"2014","journal-title":"Anticancer Res"},{"key":"bibr13-1078155217732141","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","volume":"136","author":"Froehlich TK","year":"2015","journal-title":"Int J Cancer"},{"key":"bibr14-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1027684"},{"key":"bibr15-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.172"},{"key":"bibr16-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0638"},{"key":"bibr17-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5106-484"},{"key":"bibr18-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.5b02852"},{"key":"bibr19-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1097\/NUR.0000000000000198"},{"key":"bibr20-1078155217732141","unstructured":"Toi M, Lee SJ, Ohtani S, et al. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy. In:\n                      Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium\n                      , San Antonio, TX, 8\u201312 December 2015. Philadelphia: AACR."},{"key":"bibr21-1078155217732141","doi-asserted-by":"publisher","DOI":"10.3109\/07357909909021422"},{"key":"bibr22-1078155217732141","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2001.16.3.328"},{"key":"bibr23-1078155217732141","doi-asserted-by":"publisher","DOI":"10.3109\/07357909409038226"},{"key":"bibr24-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410310306"},{"key":"bibr25-1078155217732141","doi-asserted-by":"publisher","DOI":"10.1177\/1078155209102511"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217732141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217732141","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217732141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:42Z","timestamp":1777688262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217732141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,26]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/1078155217732141"],"URL":"https:\/\/doi.org\/10.1177\/1078155217732141","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,26]]}}}